Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06519097
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-19
Brief Title:
Study of IPMN Progression Prevention With Tocotrienol SIPP-T3
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Randomized Placebo-Controlled Trial of Tocotrienol in the Prevention of Pancreatic Intraductal Papillary Mucinous Neoplasm Progression
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized double-blind placebo-controlled trial investigating whether treatment with δ-tocotrienol aka Delta-tocotrienol abbreviated as DT3 will prevent the progression of Intraductal Papillary Mucinous Neoplasm IPMN of the pancreas
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None